FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103132311> ?p ?o ?g. }

• W2103132311 endingPage "e1578" @default.
• W2103132311 startingPage "e1578" @default.
• W2103132311 abstract "In Malawi, there has been a return of Plasmodium falciparum sensitivity to chloroquine (CQ) since sulfadoxine-pyrimethamine (SP) replaced CQ as first line treatment for uncomplicated malaria. When used for prophylaxis, Amodiaquine (AQ) was associated with agranulocytosis but is considered safe for treatment and is increasingly being used in Africa. Here we compare the efficacy, safety and selection of resistance using SP or CQ+SP or artesunate (ART)+SP or AQ+SP for the treatment of uncomplicated falciparum malaria.455 children aged 1-5 years were recruited into a double-blinded randomised trial comparing SP to the three combination therapies. Using intention to treat analysis with missing outcomes treated as successes, and without adjustment to distinguish recrudescence from new infections, the day 28 adequate clinical and parasitological response (ACPR) rate for SP was 25%, inferior to each of the three combination therapies (p<0.001). AQ+SP had an ACPR rate of 97%, higher than CQ+SP (81%) and ART+SP (70%), p<0.001. Nineteen children developed a neutropenia of </=0.5x10(3) cells/microl by day 14, more commonly after AQ+SP (p = 0.03). The mutation pfcrt 76T, associated with CQ resistance, was detected in none of the pre-treatment or post-treatment parasites. The prevalence of the pfmdr1 86Y mutation was higher after treatment with AQ+SP than after SP, p = 0.002.The combination AQ+SP was highly efficacious, despite the low efficacy of SP alone; however, we found evidence that AQ may exert selective pressure for resistance associated mutations many weeks after treatment. This study confirms the return of CQ sensitivity in Malawi and importantly, shows no evidence of the re-emergence of pfcrt 76T after treatment with CQ or AQ. Given the safety record of AQ when used as a prophylaxis, our observations of marked falls in neutrophil counts in the AQ+SP group requires further scrutiny.Controlled-Trials.com ISRCTN22075368." @default.
• W2103132311 created "2016-06-24" @default.
• W2103132311 creator A5009618897 @default.
• W2103132311 creator A5015328387 @default.
• W2103132311 creator A5018692963 @default.
• W2103132311 creator A5029379996 @default.
• W2103132311 creator A5048578558 @default.
• W2103132311 creator A5061182167 @default.
• W2103132311 creator A5065510484 @default.
• W2103132311 creator A5077612350 @default.
• W2103132311 date "2008-02-13" @default.
• W2103132311 modified "2023-10-02" @default.
• W2103132311 title "Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi" @default.
• W2103132311 cites W1660290614 @default.
• W2103132311 cites W1916706013 @default.
• W2103132311 cites W1950804392 @default.
• W2103132311 cites W1972778967 @default.
• W2103132311 cites W1977699814 @default.
• W2103132311 cites W1978608749 @default.
• W2103132311 cites W1996098609 @default.
• W2103132311 cites W1999748946 @default.
• W2103132311 cites W2009503252 @default.
• W2103132311 cites W2014269864 @default.
• W2103132311 cites W2030311476 @default.
• W2103132311 cites W2033261946 @default.
• W2103132311 cites W2037241522 @default.
• W2103132311 cites W2059838568 @default.
• W2103132311 cites W2061649602 @default.
• W2103132311 cites W2061999915 @default.
• W2103132311 cites W2079395738 @default.
• W2103132311 cites W2084738144 @default.
• W2103132311 cites W2099198335 @default.
• W2103132311 cites W2104536143 @default.
• W2103132311 cites W2132831164 @default.
• W2103132311 cites W2137636253 @default.
• W2103132311 cites W2144961504 @default.
• W2103132311 cites W2158232847 @default.
• W2103132311 cites W2160884305 @default.
• W2103132311 cites W2163765308 @default.
• W2103132311 cites W2163924699 @default.
• W2103132311 cites W2167523978 @default.
• W2103132311 cites W2168912109 @default.
• W2103132311 cites W2170936619 @default.
• W2103132311 doi "https://doi.org/10.1371/journal.pone.0001578" @default.
• W2103132311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2229666" @default.
• W2103132311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18270569" @default.
• W2103132311 hasPublicationYear "2008" @default.
• W2103132311 type Work @default.
• W2103132311 sameAs 2103132311 @default.
• W2103132311 citedByCount "35" @default.
• W2103132311 countsByYear W21031323112012 @default.
• W2103132311 countsByYear W21031323112013 @default.
• W2103132311 countsByYear W21031323112014 @default.
• W2103132311 countsByYear W21031323112015 @default.
• W2103132311 countsByYear W21031323112016 @default.
• W2103132311 countsByYear W21031323112017 @default.
• W2103132311 countsByYear W21031323112020 @default.
• W2103132311 countsByYear W21031323112021 @default.
• W2103132311 countsByYear W21031323112022 @default.
• W2103132311 crossrefType "journal-article" @default.
• W2103132311 hasAuthorship W2103132311A5009618897 @default.
• W2103132311 hasAuthorship W2103132311A5015328387 @default.
• W2103132311 hasAuthorship W2103132311A5018692963 @default.
• W2103132311 hasAuthorship W2103132311A5029379996 @default.
• W2103132311 hasAuthorship W2103132311A5048578558 @default.
• W2103132311 hasAuthorship W2103132311A5061182167 @default.
• W2103132311 hasAuthorship W2103132311A5065510484 @default.
• W2103132311 hasAuthorship W2103132311A5077612350 @default.
• W2103132311 hasBestOaLocation W21031323111 @default.
• W2103132311 hasConcept C114851261 @default.
• W2103132311 hasConcept C126322002 @default.
• W2103132311 hasConcept C203014093 @default.
• W2103132311 hasConcept C2776120307 @default.
• W2103132311 hasConcept C2776694085 @default.
• W2103132311 hasConcept C2776992834 @default.
• W2103132311 hasConcept C2776999253 @default.
• W2103132311 hasConcept C2777035104 @default.
• W2103132311 hasConcept C2777063308 @default.
• W2103132311 hasConcept C2777425658 @default.
• W2103132311 hasConcept C2777616469 @default.
• W2103132311 hasConcept C2778048844 @default.
• W2103132311 hasConcept C2778059366 @default.
• W2103132311 hasConcept C2778301690 @default.
• W2103132311 hasConcept C2778371730 @default.
• W2103132311 hasConcept C2780441369 @default.
• W2103132311 hasConcept C71924100 @default.
• W2103132311 hasConcept C86803240 @default.
• W2103132311 hasConcept C89423630 @default.
• W2103132311 hasConcept C98274493 @default.
• W2103132311 hasConceptScore W2103132311C114851261 @default.
• W2103132311 hasConceptScore W2103132311C126322002 @default.
• W2103132311 hasConceptScore W2103132311C203014093 @default.
• W2103132311 hasConceptScore W2103132311C2776120307 @default.
• W2103132311 hasConceptScore W2103132311C2776694085 @default.
• W2103132311 hasConceptScore W2103132311C2776992834 @default.
• W2103132311 hasConceptScore W2103132311C2776999253 @default.
• W2103132311 hasConceptScore W2103132311C2777035104 @default.
• W2103132311 hasConceptScore W2103132311C2777063308 @default.

• next